Skip to content
To the full analysis

Akso Health Group stock: balance sheet and debt

AHG
$1.35Closing price of 12 Nov 2026MEQIRI Score 35 out of 100

Akso Health Group has a debt to equity ratio of 0.

Daily figure as of 13 Nov 2026

Debt / Equity
0
Interest coverage
no data
Current ratio
20
Cash & equivalents
$170.57K
Total assets
$189.63M
Equity ratio
95.4%
Goodwill and intangible assets
$58.32K
not split out
Net debt
$205.09K

Total assets and equity ratio

How large the balance sheet of Akso Health Group is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2015$7.39Mnot reported separatelynot reported separately45.3%−$954.68K
2016$22.39Mnot reported separatelynot reported separately62.6%−$7.82M
2017$28.38Mnot reported separatelynot reported separately82.8%−$19.23M
2018$163.89M$331.58Knot split out85.4%−$132.62M
2019$173.26Mnot reported separatelynot reported separately73.0%−$37.37M
2020$80.48Mnot reported separatelynot reported separately59.8%$14.09M
2021$31.69Mnot reported separatelynot reported separately54.5%−$5.13M
2022$62.81Mnot reported separatelynot reported separately19.6%−$18.43M
2023$20.46Mnot reported separatelynot reported separately43.2%−$7.92M
2024$142.02Mnot reported separatelynot reported separately97.5%−$85.17M
2025$214.95M$18.71M$10.83M92.6%−$176.15M
2026$189.63M$58.32Knot split out95.4%$205.09K

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2015$954.68K$3.35M$00
2016$7.82M$14.01M$00
2017$19.23M$23.5M$00
2018$132.62M$140.04M$00
2019$57.37M$126.5M$20M0.16
2020$6.67M$48.1M$20.75M0.43
2021$15.13M$17.27M$10M0.58
2022$18.43M$12.28M$00
2023$7.92M$8.73M$00
2024$85.17M$138.37M$00
2025$176.23M$199.12M$81.74K0
2026$170.57K$180.93M$375.66K0

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2026, period end 31 Mar 2026
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 8 Aug 2025)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy